Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517242 | 1.00 | RECQL (0.32) | RECQLPOLBHPGDPKMTSHR | |
| SCHEMBL516867 | 0.82 | PIK3CD (0.38) | RECQLPOLBHPGDPKMMEN1 | |
| SCHEMBL516868 | 0.82 | PIK3CD (0.38) | RECQLPOLBHPGDPKMMEN1 | |
| SCHEMBL19666475 | 0.78 | POLB (0.51) | RECQLPOLBHPGDPKMTSHR | |
| SCHEMBL19666476 | 0.78 | POLB (0.51) | RECQLPOLBHPGDPKMTSHR | |
| SCHEMBL1908625 | 0.78 | MAPT (0.40) | RECQLPOLBHPGDPKMTSHR | |
| SCHEMBL19465724 | 0.75 | TSHR (0.34) | POLBHPGDPKMTSHRSMN1; SMN2 | |
| SCHEMBL1908622 | 0.75 | TSHR (0.34) | POLBHPGDPKMTSHRSMN1; SMN2 | |
| SCHEMBL19063336 | 0.75 | TSHR (0.43) | RECQLHPGDTSHRSMN1; SMN2CNR2 | |
| SCHEMBL19065051 | 0.75 | TSHR (0.43) | RECQLHPGDTSHRSMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | RECQL 2744/4885POLB 1792/4885HPGD 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.